Related Experiment Video

Updated: Dec 10, 2025

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.4K

Omeprazole nanoparticles suspension: Development of a stable liquid formulation with a view to pediatric

Helissara Silveira Diefenthaeler1, Mariana Domingues Bianchin2, Morgana Souza Marques3

  • 1Programa de Pós-Graduação em Nanotecnologia Farmacêutica, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil.

International Journal of Pharmaceutics
|September 1, 2020
PubMed

Insights

Researchers developed omeprazole (OME) nanoparticles for a liquid pediatric formulation. These nanoparticles effectively protected mouse stomachs from ulcers, offering a new therapeutic strategy for children.

Area of Science:

  • Pharmaceutical Technology
  • Nanomedicine
  • Pediatric Pharmacology

Background:

  • Omeprazole (OME) is crucial for treating pediatric gastric hypersecretion disorders.
  • A readily available liquid pediatric formulation of OME is currently lacking.
  • This necessitates the development of novel drug delivery systems for pediatric use.

Purpose of the Study:

  • To develop omeprazole (OME) loaded nanoparticles.
  • To create a stable liquid pharmaceutical dosage form for pediatric administration.
  • To evaluate the anti-ulcerogenic efficacy of the OME nanoparticles.

Main Methods:

  • Nanoparticle formulation using Eudragit® RS100 core and Eudragit® L100-55 pH-sensitive coating.
  • Nanoprecipitation method for nanoparticle preparation.
  • Characterization of nanoparticle size, PDI, zeta potential, and encapsulation efficiency.
  • In vivo assessment of pharmacological activity using ethanol-induced ulcer model in mice.

Main Results:

  • Formulated OME nanoparticles exhibited a mean diameter of 174 nm (±17) and a PDI of 0.229 (±0.01).
  • Zeta potential was measured at -13 mV (±2.60), indicating good stability.
  • Encapsulation efficiency reached 68.1%, and in vivo studies demonstrated significant gastric protection against ethanol-induced ulcers.

Conclusions:

  • The developed OME nanoparticles are suitable for a liquid pharmaceutical suspension.
  • This formulation presents a viable and effective therapeutic strategy for pediatric patients.
  • The nanoparticle suspension offers a promising alternative for pediatric administration of omeprazole.

Keywords:
Eudragit L100-55Eudragit RS100Omeprazole nanoparticlesPediatric use

More Related Videos

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.7K
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
147
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
172
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.4K
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
106
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
91